Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00762476|
Recruitment Status : Completed
First Posted : September 30, 2008
Results First Posted : April 16, 2012
Last Update Posted : April 16, 2012
|Condition or disease||Intervention/treatment||Phase|
|Common Cold||Drug: 3804-250A Drug: 3804-291||Phase 2|
Rhinovirus infections are the most frequent cause up to 80% of cold illnesses during the fall rhinovirus season. While viral upper respiratory infections are generally mild and self-limited, they are associated with an enormous economic burden both in lost productivity and in expenditures for treatment. Rhinovirus infection is frequently associated with medical complications that have substantial morbidity such as acute otitis media and exacerbation of asthma.
Marketed treatment options for rhinovirus consist primarily of symptomatic cold remedies have only modest effects on specific cold symptoms. 3804-250A is under investigation for the prevention of rhinovirus infection by interruption of person-to-person transmission appears to be technologically and economically feasible.
The study is a randomized, double-blind, Placebo controlled, multi-site, parallel design clinical trial conducted in the natural setting. The study will be conducted during a 10-week period during the fall rhinovirus epidemic season. Healthy, normal subjects will be recruited and randomly assigned to the AV Lotion or Placebo control group. Subjects will use the assigned test product on a defined schedule and will record the presence of cold illness symptoms daily. Subjects will return to the study site every week during the study for review and clarification of study diary entries, for review and assessment of compliance, for specimen collection for rhinovirus PCR.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||411 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II EFFICACY TRIAL OF AV LOTION (FORMULA NO. 3804-250A) FOR THE PREVENTION OF COLD ILLNESS IN HUMAN SUBJECTS|
|Study Start Date :||August 2008|
|Primary Completion Date :||November 2008|
|Study Completion Date :||November 2008|
|Placebo Comparator: Placebo||
- The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses. [ Time Frame: 10 weeks ]Comparison of the total number of incidence of cold illnesses over the course of the study per 100 subjects in each treatment group
- Rhinovirus Infections. [ Time Frame: 10 weeks ]The incidence of rhinovirus infections
- Rhinovirus-associated Colds [ Time Frame: 10 weeks ]The incidence of rhinovirus-associated cold illnesses.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00762476
|United States, New Jersey|
|TKL Research, Inc.|
|Paramus, New Jersey, United States, 07652|
|United States, Virginia|
|University of Virginia School of Medicine|
|Charlottesville, Virginia, United States, 22908|
|Principal Investigator:||Ronald B Turner, MD||University of Virginia School of Medicine|
|Principal Investigator:||Michael E Casser, MD||TKL Research, Inc.|